Humalog Reviews: How It Compares to Novolog

Novolog (insulin aspart) and Humalog (insulin lispro) are both FDA-approved rapid-acting insulin analogs used at mealtimes to cover the glucose rise from food, in contrast to long-acting basal insulins like Lantus or Tresiba, which cover background needs between meals. Humalog was approved first, in 1996; Novolog followed in 2000. Both are available as standard formulations and as faster-onset variants (Fiasp for aspart, Lyumjev for lispro), and lower-cost versions exist for lispro through the biosimilar Admelog and an authorized generic.

The useful question for most patients is not which drug is pharmacologically better, but which one your insurance formulary, pump or pen device, and daily routine make easiest to use correctly and consistently. Head-to-head trials have not shown a clinically meaningful difference between aspart and lispro in A1C, hypoglycemia, or quality of life for typical mealtime use, so cost, device compatibility, and formulary tier usually decide the choice in practice.

What established regulators and guidelines say

Both drugs are FDA-approved for subcutaneous injection to control blood glucose in adults and children with diabetes, and both are approved for use in insulin pumps (continuous subcutaneous infusion). Their current FDA-approved prescribing information is the primary source for approved dosing, contraindications, and warnings:

• Humalog (insulin lispro) label: consult the current FDA-approved prescribing information available through the FDA's drug label database
• Novolog (insulin aspart) label: consult the current FDA-approved prescribing information available through the FDA's drug label database

Both labels specify injection within about 15 minutes before a meal (or immediately after eating in some circumstances), which is faster than the 30-minute pre-meal window required for older regular human insulin. Neither label recommends one product over the other for a specific type of patient; the labels describe pharmacology and dosing for each drug independently rather than making a comparative claim.

The American Diabetes Association's Standards of Care describes basal-bolus therapy (a long-acting insulin plus a rapid-acting insulin at meals) as standard for most people with type 1 diabetes, and mealtime insulin as an option added to basal insulin or oral agents in type 2 diabetes when glucose remains above target. The current Standards of Care document is available at https://diabetesjournals.org/care/issue/47/Supplement_1. It does not recommend aspart over lispro or vice versa for mealtime coverage.

Onset, peak, and duration: how much do the differences actually matter

Both insulins begin lowering glucose within roughly 10 to 15 minutes of subcutaneous injection and have an effective duration of action in the range of 3 to 5 hours, per their FDA labels. Some pharmacokinetic studies have reported a slightly earlier or more pronounced peak with one agent versus the other, generally within the same one-to-two-hour window after injection. These differences are measured in minutes, not hours, and the size and clinical relevance of any peak-timing difference should be confirmed against the specific studies before being treated as a prescribing rule; the two agents are commonly described in clinical practice as functionally interchangeable for typical meal coverage.

Faster-onset formulations exist for both drugs: Fiasp (faster aspart) and Lyumjev (faster lispro) are formulated to reach effective insulin levels sooner after injection than their standard counterparts, which can matter more for post-meal glucose control than the difference between standard Novolog and standard Humalog. Not every insulin pump algorithm is validated for these faster formulations, so pump users should confirm compatibility with the device manufacturer before switching.

Absorption for any rapid-acting insulin is affected by injection site (abdomen generally absorbs faster than thigh or upper arm), local blood flow, temperature, and whether the tissue at the injection site has developed lipohypertrophy from repeated use in the same spot. These practical factors often move a person's real-world response more than the small labeled difference between aspart and lispro.

Dosing and injection timing

Standard label guidance for both drugs is to inject within about 15 minutes before eating. For people with unpredictable eating patterns, such as young children or people with gastroparesis, injecting immediately after eating and adjusting the dose to what was actually consumed is a recognized clinical approach, but the specific adjustment should come from the prescribing clinician rather than a general formula. This article does not provide individualized dosing instructions; insulin dosing, including correction-dose calculations, needs to be set and periodically reassessed by the clinician managing your diabetes care, because the right dose depends on body weight, insulin sensitivity, kidney function, activity level, and other medications.

Mixing a rapid-acting analog with NPH insulin in the same syringe is technically possible but is uncommon now that long-acting analogs are standard; neither aspart nor lispro should be mixed with glargine or degludec in the same syringe.

Side effects and safety

Hypoglycemia is the primary risk shared by both drugs, as it is with any insulin. Reported rates of hypoglycemia vary widely across studies depending on population, insulin regimen, and how hypoglycemia is defined, so a single pooled number should not be treated as a fixed risk for an individual patient; ask your prescriber what monitoring and dose-adjustment plan applies to your regimen. Severe hypoglycemia requiring assistance from another person is uncommon but is a medical emergency; seek urgent care for confusion, loss of consciousness, or seizure associated with low blood glucose.

Injection-site reactions, including lipohypertrophy (thickened, lumpy tissue from repeated injections at the same spot), occur with both drugs and can cause erratic absorption even when the dose is measured correctly. Rotating injection sites across the abdomen, thighs, and upper arms reduces this risk. Generalized allergic reactions to insulin, including urticaria or anaphylaxis, are rare with either agent. Weight gain commonly accompanies improved glucose control with any insulin therapy; the magnitude varies by individual and regimen and should be discussed with your care team rather than assumed from a general figure.

CGM versus fingerstick testing alongside rapid-acting insulin

Continuous glucose monitoring (CGM) gives a glucose reading every few minutes along with a trend arrow, which changes bolus decisions in ways a single fingerstick cannot. A falling trend arrow at mealtime, for example, is a signal to a clinician-guided plan for whether to lower or delay the mealtime dose. Randomized trials in type 1 and type 2 diabetes, including the DIAMOND, IMPACT, and MOBILE studies, have reported that CGM use is associated with greater A1C improvement and less time spent in hypoglycemia than fingerstick testing alone. Exact effect sizes from these trials vary by population and should be checked against the original publications rather than repeated as a fixed number; the general direction of benefit for CGM over fingerstick-only monitoring is well established in current practice guidance.

The ADA Standards of Care recommend CGM for essentially all adults with type 1 diabetes and for adults with type 2 diabetes on multiple daily injections or an insulin pump. CGM reduces but does not eliminate the need for fingerstick testing; a fingerstick check is still advised when CGM readings do not match symptoms or during periods that require sensor calibration.

Where oral agents and GLP-1 medicines fit before mealtime insulin is added

Many patients reach a rapid-acting insulin only after metformin, other oral agents, or a GLP-1 receptor agonist have been tried. Metformin remains the typical first-line oral agent for type 2 diabetes because of its safety record, low cost, and lack of hypoglycemia risk on its own.

GLP-1 receptor agonists (semaglutide, liraglutide, and others) lower blood glucose in a glucose-dependent way, meaning they carry little hypoglycemia risk unless combined with insulin or a sulfonylurea, and they typically also produce weight loss. Cardiovascular outcome trials for several GLP-1 agonists, including SUSTAIN-6 (semaglutide) and LEADER (liraglutide), reported reductions in cardiovascular events in people with type 2 diabetes and elevated cardiovascular risk. Exact effect sizes and the specific populations studied should be confirmed against the original trial publications before being applied to an individual patient, since eligibility criteria varied across these trials.

SGLT-2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) lower glucose by increasing urinary glucose excretion and, in trials such as EMPA-REG OUTCOME and CREDENCE, have shown cardiovascular and kidney benefits in people with type 2 diabetes and additional risk factors. DPP-4 inhibitors (sitagliptin, linagliptin, and others) are generally weight-neutral and lower A1C more modestly, without the same cardiovascular or renal outcome data. SGLT-2 inhibitors carry an FDA warning about diabetic ketoacidosis risk, which is a particular concern in type 1 diabetes and in anyone on insulin who reduces carbohydrate intake sharply or becomes acutely ill; DPP-4 inhibitors do not carry this warning and do not add meaningfully to hypoglycemia risk when combined with rapid-acting insulin.

A patient on maximally tolerated metformin and a GLP-1 agonist who still has an A1C well above target, particularly with high fasting glucose, is a typical candidate for adding basal insulin first, with mealtime insulin added afterward if after-meal glucose spikes remain uncontrolled.

Choosing a basal partner: Lantus versus Tresiba versus Toujeo

Rapid-acting insulin is almost always paired with a long-acting basal insulin, and the basal choice affects overall day-to-day stability. Lantus (glargine U-100) has a long track record and a relatively flat profile without a pronounced peak. Tresiba (insulin degludec) has a longer duration of action and more day-to-day flexibility in injection timing; a large randomized trial (DEVOTE) comparing degludec to glargine in people with type 2 diabetes at high cardiovascular risk reported fewer episodes of severe hypoglycemia, including at night, with degludec. Toujeo (glargine U-300) is a more concentrated formulation with a somewhat longer duration than standard Lantus, which can help patients who need a large basal dose and find the injection volume uncomfortable. All three are compatible with either Novolog or Humalog as the mealtime component. The current FDA-approved Tresiba prescribing information is available through the FDA's drug label database.

Decision framework: matching the rapid-acting insulin to the patient

This table reflects general prescribing and access patterns rather than individualized medical advice; the right choice for a specific patient depends on their prescriber's assessment.

Do head-to-head trials show one is better?

Direct comparator trials between aspart and lispro are older and smaller than the landmark trials used to support each drug's own approval, and some report only small, short-lived differences in after-meal glucose that did not translate into differences in A1C or hypoglycemia over several months of follow-up. Diabetes specialty guidelines generally describe rapid-acting analogs as a class that is preferred over regular human insulin for mealtime dosing, without recommending one specific rapid-acting analog over another. Readers who want the exact comparator trial data (sample sizes, statistical results) should ask their prescriber or a medical librarian to pull the specific published studies, since precise figures from older comparator trials are easy to misattribute and are not repeated here as exact numbers.

What is established, what is plausible, and what is not established

Established: both drugs are FDA-approved rapid-acting insulin analogs with onset around 10 to 15 minutes and duration of roughly 3 to 5 hours; both are approved for pump use; faster formulations (Fiasp, Lyumjev) exist for patients who want a shorter injection-to-effect delay; CGM use is associated with better glucose outcomes than fingerstick-only monitoring in people using intensive insulin regimens.

Plausible but not firmly established for typical patients: that a several-minute difference in peak timing between standard aspart and standard lispro produces a meaningful difference in day-to-day glucose control for most people.

Not established: that either Novolog or Humalog is superior to the other in hard outcomes such as A1C, severe hypoglycemia, or quality of life for the general population of insulin users; guidelines do not differentiate between the two for mealtime dosing.

When to seek urgent care

Confusion, slurred speech, loss of consciousness, or a seizure in someone using insulin is a medical emergency and needs immediate treatment, including glucagon if available and calling emergency services; this is not something to manage by adjusting the next dose. Repeated unexplained hypoglycemia, signs of diabetic ketoacidosis (nausea, vomiting, abdominal pain, rapid breathing, fruity breath odor) in anyone on insulin or an SGLT-2 inhibitor, or a severe allergic reaction after an insulin injection all warrant prompt medical evaluation rather than watchful waiting.